Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450-dependent 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to accumulation of toxic methylated sterols and depletion of ergosterol, disrupting membrane integrity and function.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Vaginal candidiasis,Oropharyngeal and esophageal candidiasis,Systemic candidiasis (including candidemia, disseminated candidiasis, and urinary tract infections),Cryptococcal meningitis,Prophylaxis of candidiasis in bone marrow transplant recipients,Off-label: Treatment of coccidioidomycosis, blastomycosis, histoplasmosis, and tinea infections
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
400 mg IV loading dose on day 1, then 200 mg IV once daily; for invasive candidiasis or cryptococcal meningitis, 800 mg IV loading dose then 400 mg IV once daily
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function. This long half-life allows once-daily dosing and achieves steady-state after 5-7 days.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Fluconazole is primarily metabolized by the liver via the cytochrome P450 system, specifically CYP2C9 and CYP3A4. It also inhibits CYP2C9, CYP2C19, and CYP3A4. Approximately 80% of a dose is excreted unchanged in urine; the remainder is metabolized to inactive metabolites.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal elimination of unchanged drug accounts for approximately 80% of the dose, with 11% as metabolites. Biliary/fecal excretion is minimal (<5%).
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
11-12% bound to plasma proteins (primarily albumin).
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Volume of distribution is approximately 0.7 L/kg (range 0.6-0.8 L/kg), indicating extensive distribution into total body water and tissues, including CSF, eyes, and urine.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Bioavailability of oral fluconazole is >90% (oral solution and tablets). IV administration (as in this product) provides 100% bioavailability.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
Cr Cl >50 m L/min: no adjustment; Cr Cl ≤50 m L/min (not on dialysis): administer 50% of recommended dose; hemodialysis: one full dose after each dialysis session
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Child-Pugh A and B: no adjustment required; Child-Pugh C: limited data, use with caution and monitor closely
No dosage adjustment required for hepatic impairment.
Loading dose: 12 mg/kg IV (max 800 mg) on day 1; maintenance: 6 mg/kg IV once daily (max 400 mg); for invasive candidiasis or cryptococcal meningitis: loading 12 mg/kg IV (max 800 mg), then 6-12 mg/kg IV once daily (max 800 mg)
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
No specific dose adjustment; use based on renal function; age-related decline in renal function should be considered and Cr Cl calculated for dosing
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
No FDA black box warning.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Hepatotoxicity: Monitor liver function tests; risk of hepatic necrosis and death.,QT prolongation: Risk of torsades de pointes, especially in patients with electrolyte abnormalities or concurrent QT-prolonging drugs.,Fetal risk: Use in pregnancy only if clearly needed, especially during first trimester (potential for teratogenicity).,Drug interactions: Increased risk of bleeding with warfarin; increased risk of toxicity from cyclosporine, phenytoin, and oral hypoglycemics; avoid coadministration with terfenadine, cisapride, and pimozide due to risk of QT prolongation.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypersensitivity to fluconazole or any excipient,Coadministration with terfenadine, cisapride, or pimozide (risk of serious cardiac arrhythmias),Coadministration with ergot alkaloids (risk of ergotism),Use in pregnancy (especially high-dose therapy) unless potential benefit outweighs risk
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No significant food interactions. However, avoid grapefruit and grapefruit juice as it may increase fluconazole levels. Maintain consistent intake of caffeine and alcohol as they may increase side effects like dizziness or liver strain.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
First trimester: Fluconazole is associated with a dose-dependent risk of congenital malformations, including craniofacial, skeletal, and cardiac defects, particularly with prolonged use of high doses (≥400 mg/day). Epidemiological data suggest a small increased risk of spontaneous abortion and major malformations with low-dose exposure. Second and third trimesters: Limited evidence of fetal toxicity; however, risks include preterm delivery and low birth weight with high-dose therapy. FDA Pregnancy Category D.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Fluconazole is excreted into breast milk in concentrations similar to maternal plasma. The milk-to-plasma (M/P) ratio is approximately 1.0. In full-term infants with normal renal function, exposure is low and considered compatible with breastfeeding. However, caution is advised in preterm infants or those with renal impairment. Monitor infant for diarrhea, jaundice, or feeding difficulties.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Increased plasma volume and enhanced renal clearance during pregnancy may require higher doses to maintain therapeutic levels, especially in the third trimester. For systemic infections, consider empiric dose increase by 50-100% or adjust based on therapeutic drug monitoring (target trough: 8-12 mg/L). Do not exceed 400 mg/day unless treating severe infections (e.g., coccidioidal meningitis) under specialist guidance.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Fluconazole in 0.9% Na Cl is an IV formulation; ensure compatibility before administration. May prolong QT interval, especially at high doses (≥400 mg/day); monitor ECG in patients with electrolyte disturbances or concurrent QT-prolonging drugs. Adjust dose in renal impairment (Cr Cl <50 m L/min: reduce by 50%). Maintain adequate hydration to prevent crystalluria. Do not mix with other medications in same IV line unless compatibility confirmed.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Take this medication exactly as prescribed by your doctor.,Inform your doctor if you have liver disease, kidney problems, or heart rhythm disorders.,Avoid driving or operating machinery until you know how this medication affects you.,Report signs of liver toxicity: dark urine, pale stools, yellowing of skin or eyes, persistent nausea.,Contact your doctor if you experience fast or irregular heartbeat, dizziness, or fainting.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Cobimetinib is primarily metabolized by CYP3A4, while fluconazole is a moderate inhibitor of CYP3A4. Coadministration may lead to increased cobimetinib exposure, potentially elevating the risk of adverse effects such as myopathy, hepatotoxicity, and cutaneous toxicities. Fluconazole serum concentration is unlikely to be significantly affected by cobimetinib."
"Propafenone, a class IC antiarrhythmic agent, is metabolized primarily by cytochrome P450 2D6 (CYP2D6) and to a lesser extent by CYP3A4 and CYP1A2. Fluconazole, a potent inhibitor of CYP2C9 and a moderate inhibitor of CYP3A4, can increase the plasma concentration of propafenone by inhibiting its CYP3A4-mediated metabolism. This can lead to enhanced antiarrhythmic effects and an increased risk of proarrhythmia, including ventricular tachycardia and other serious adverse events such as QT prolongation."
"Fluconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), can significantly reduce the hepatic clearance of hydrocortisone, a corticosteroid metabolized primarily by CYP3A4. This interaction leads to increased systemic exposure to hydrocortisone, potentially resulting in exaggerated corticosteroid effects such as hyperglycemia, immunosuppression, and adrenal suppression. Clinically, patients may experience symptoms of Cushing's syndrome or require dose adjustments to avoid toxicity."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUCONAZOLE IN SODIUM CHLORIDE 0.9% vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450-dependent 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to accumulation of toxic methylated sterols and depletion of ergosterol, disrupting membrane integrity and function.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUCONAZOLE IN SODIUM CHLORIDE 0.9% and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUCONAZOLE IN SODIUM CHLORIDE 0.9% is: 400 mg IV loading dose on day 1, then 200 mg IV once daily; for invasive candidiasis or cryptococcal meningitis, 800 mg IV loading dose then 400 mg IV once daily. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUCONAZOLE IN SODIUM CHLORIDE 0.9% and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUCONAZOLE IN SODIUM CHLORIDE 0.9% is classified as Category A/B. First trimester: Fluconazole is associated with a dose-dependent risk of congenital malformations, including craniofacial, skeletal, and cardiac defects, particularly with prolonge. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.